Equities Analysts Offer Predictions for AGIO FY2025 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at HC Wainwright increased their FY2025 earnings estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Wednesday, November 19th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings of ($7.19) per share for the year, up from their prior estimate of ($7.21). HC Wainwright currently has a “Buy” rating and a $48.00 price target on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.92) EPS, Q1 2026 earnings at ($2.04) EPS, Q2 2026 earnings at ($2.12) EPS, Q3 2026 earnings at ($2.10) EPS, Q4 2026 earnings at ($2.11) EPS, FY2026 earnings at ($8.37) EPS, FY2027 earnings at ($7.87) EPS, FY2028 earnings at ($6.61) EPS and FY2029 earnings at ($4.63) EPS.

Several other equities analysts also recently commented on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, November 19th. Bank of America lowered their target price on shares of Agios Pharmaceuticals from $54.00 to $32.00 and set a “buy” rating for the company in a research note on Thursday, November 20th. The Goldman Sachs Group cut their price target on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a report on Thursday, November 20th. Truist Financial set a $32.00 price objective on shares of Agios Pharmaceuticals in a report on Monday. Finally, Wall Street Zen downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $35.50.

Agios Pharmaceuticals Stock Performance

AGIO opened at $26.49 on Monday. The stock’s 50 day moving average price is $39.71 and its 200-day moving average price is $36.90. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $62.45. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -3.78 and a beta of 0.89.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The company had revenue of $12.90 million for the quarter, compared to analyst estimates of $10.49 million. During the same period in the prior year, the company posted $16.22 EPS. The firm’s revenue for the quarter was up 43.3% on a year-over-year basis.

Institutional Investors Weigh In On Agios Pharmaceuticals

Large investors have recently modified their holdings of the company. NewEdge Advisors LLC purchased a new stake in Agios Pharmaceuticals during the 1st quarter worth about $40,000. First Horizon Corp purchased a new stake in Agios Pharmaceuticals during the third quarter worth approximately $45,000. CWM LLC raised its holdings in Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 996 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Agios Pharmaceuticals by 16.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 320 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth approximately $79,000.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 3,302 shares of the stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $43.92, for a total transaction of $145,023.84. Following the transaction, the insider owned 61,727 shares in the company, valued at approximately $2,711,049.84. This represents a 5.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Theodore James Jr. Washburn sold 8,546 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $36.87, for a total value of $315,091.02. Following the transaction, the insider owned 868 shares in the company, valued at approximately $32,003.16. This represents a 90.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 16,099 shares of company stock worth $620,092. Company insiders own 4.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.